- Home
- HRMY vs STAA Comparison
HRMY vs STAA Comparison
Compare HRMY & STAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- STAA
- Stock Information
- Founded
- HRMY 2017
- STAA 1982
- Country
- HRMY United States
- STAA United States
- Employees
- HRMY N/A
- STAA N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- STAA Ophthalmic Goods
- Sector
- HRMY Health Care
- STAA Health Care
- Exchange
- HRMY Nasdaq
- STAA Nasdaq
- Market Cap
- HRMY 2.1B
- STAA 1.4B
- IPO Year
- HRMY 2020
- STAA N/A
- Fundamental
- Price
- HRMY $32.06
- STAA $27.16
- Analyst Decision
- HRMY Strong Buy
- STAA Hold
- Analyst Count
- HRMY 9
- STAA 8
- Target Price
- HRMY $55.33
- STAA $22.50
- AVG Volume (30 Days)
- HRMY 696.1K
- STAA 674.6K
- Earning Date
- HRMY 10-28-2025
- STAA 10-29-2025
- Dividend Yield
- HRMY N/A
- STAA N/A
- EPS Growth
- HRMY 58.41
- STAA N/A
- EPS
- HRMY 3.10
- STAA N/A
- Revenue
- HRMY $772,527,000.00
- STAA $224,449,000.00
- Revenue This Year
- HRMY $20.09
- STAA N/A
- Revenue Next Year
- HRMY $16.86
- STAA $27.24
- P/E Ratio
- HRMY $10.40
- STAA N/A
- Revenue Growth
- HRMY 17.74
- STAA N/A
- 52 Week Low
- HRMY $26.47
- STAA $13.50
- 52 Week High
- HRMY $41.61
- STAA $38.60
- Technical
- Relative Strength Index (RSI)
- HRMY 29.47
- STAA 56.69
- Support Level
- HRMY $31.61
- STAA $27.52
- Resistance Level
- HRMY $37.05
- STAA $28.13
- Average True Range (ATR)
- HRMY 1.16
- STAA 0.48
- MACD
- HRMY -0.56
- STAA -0.35
- Stochastic Oscillator
- HRMY 6.82
- STAA 12.86
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About STAA STAAR Surgical Company
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.